AICAR
AICAR (AMPK Activator)
A compound that activates the same metabolic switch as exercise, triggering fat burning, improved insulin sensitivity, and increased endurance capacity without physical training.

AICAR is a compound that tricks your cells into thinking you just exercised, even when you have been completely sedentary. It activates the same metabolic switch that exercise turns on, triggering your body to burn fat, improve insulin sensitivity, and build more mitochondria -- the energy factories inside your cells. In 2008, researchers at the Salk Institute made worldwide headlines when they showed that sedentary mice given AICAR for four weeks increased their running endurance by 44 percent without any training whatsoever. Media outlets called it 'exercise in a pill.'
Your body actually produces AICAR naturally as part of normal metabolism. When you take it as a supplement, it gets converted inside your cells to a compound called ZMP that mimics the low-energy signal your cells normally send during exercise. This activates AMPK (AMP-activated protein kinase), which scientists often call your body's master metabolic switch. AMPK is the enzyme that drives many of the health benefits of both exercise and caloric restriction, so activating it provides some of the same metabolic improvements.
Professional athletes noticed the research quickly, and within a year of the 2008 study, WADA banned AICAR. In 2012, Spanish cyclists were arrested for trafficking it as a 'next generation superdrug.' AICAR is not FDA approved for human use, is banned by WADA for competitive athletes, and is available only as a research chemical. Human dosing has not been clinically established, and the animal research doses used in the landmark studies would be cost-prohibitive and potentially unsafe for humans.
How It Works
When your cells run low on energy during exercise, levels of AMP rise relative to ATP (your cells' energy currency). Your cells sense this shift through AMPK, which then triggers a cascade of adaptations to conserve energy and improve metabolic efficiency. AICAR bypasses the need for actual exercise -- once it enters your cells, it gets converted to ZMP, which looks enough like AMP to flip the AMPK switch even when your energy levels are completely normal. Your cells respond as if you just ran a marathon.
Once AMPK activates, several important things happen simultaneously. Your muscles start pulling glucose out of your blood without needing insulin, which is the same blood-sugar-lowering effect you see with exercise. Your cells begin burning more fat for fuel because AMPK removes the brakes on fatty acid oxidation, letting your mitochondria burn through fat stores more efficiently. And your body builds more mitochondria by activating PGC-1-alpha, the master switch for mitochondrial biogenesis -- more mitochondria means better endurance capacity and overall metabolic health.
AICAR also shifts your muscle composition toward slow-twitch, fatigue-resistant fibers -- the same type endurance athletes develop through years of training. It upregulates genes involved in oxidative metabolism including UCP3, CPT1, and PDK4. However, research has revealed that AICAR also has effects independent of AMPK, including impacts on purine and pyrimidine synthesis pathways, which is important to consider when evaluating its full biological effects.
Potential Benefits
Endurance Enhancement
The most dramatic finding from AICAR research is its effect on endurance. Sedentary mice treated for 4 weeks ran 23 percent longer and 44 percent further without any exercise training. The compound induced 32 genes linked to oxidative metabolism, representing a genuine shift in the muscles' capacity for sustained energy production. While human responses may differ from mice, the magnitude of improvement was remarkable.
Glucose Metabolism
AICAR improves how your body handles blood sugar by increasing glucose uptake in skeletal muscle and enhancing insulin sensitivity, producing effects similar to those seen with exercise training. This has potential applications for insulin resistance and type 2 diabetes research, particularly for people who cannot exercise due to physical limitations.
Fat Metabolism
AICAR promotes fat burning by suppressing the creation of new fatty acids while simultaneously promoting the breakdown of existing fat stores. Animal studies showed reduced abdominal fat mass. The compound essentially shifts your metabolism toward using fat as a primary fuel source, similar to what happens during sustained aerobic exercise.
Mitochondrial Enhancement
AICAR promotes the creation of new mitochondria through activation of PGC-1-alpha, the master regulator of mitochondrial biogenesis. It increases the total mitochondrial content in muscles, improves mitochondrial function and efficiency, and enhances the overall oxidative capacity of cells. More and better-functioning mitochondria translate to improved energy production and metabolic health.
Cardiovascular Protection
In cardiac studies, AICAR has demonstrated protective effects during ischemia, which is when blood flow to the heart is restricted. These cardioprotective properties suggest the compound may help protect heart tissue during periods of reduced blood supply, though this has primarily been studied in research settings.
Diabetic Neuropathy Research
A 2024 study showed AICAR prevented and reversed diabetic peripheral neuropathy in mouse models, improving insulin sensitivity, glucose and lipid metabolism, and regulating mitochondrial function through AMPK activation. This is particularly significant for diabetic patients who cannot exercise but could potentially benefit from exercise-mimetic metabolic activation.
Anti-Inflammatory Effects
AICAR has demonstrated anti-inflammatory properties including reduced inflammation in fat tissue, suppressed NF-kB signaling in immune cells, and reduced production of pro-inflammatory molecules. These effects may contribute to its metabolic benefits, as chronic inflammation is closely linked to insulin resistance and metabolic dysfunction.
What the Research Shows
The landmark 2008 study by Narkar and colleagues published in Cell is the foundation of AICAR research. Sedentary mice treated with AICAR for 4 weeks at 500 mg/kg/day showed a 23 percent increase in running time and a 44 percent increase in running distance. The treatment induced 32 genes linked to oxidative metabolism, decreased abdominal fat mass, increased oxygen consumption, and the effects were mediated through the AMPK-PPARdelta pathway. This was the study that earned AICAR the 'exercise in a pill' label.
Visnjic and colleagues published a systematic review in Cells in 2021 confirming that AICAR is one of the most commonly used AMPK activators in research. They documented both AMPK-dependent and AMPK-independent effects, noted AICAR's immediate impact on the sports community and the resulting WADA ban, and emphasized the need for caution in interpreting AICAR-based studies because some effects may not be mediated through AMPK at all.
Hinder and colleagues published a 2024 study in the International Journal of Molecular Sciences showing AICAR prevented and reversed diabetic peripheral neuropathy in mouse models of both Type 1 and Type 2 diabetes. The mechanism involved AMPK phosphorylation and mitochondrial regulation, with improvements in insulin sensitivity, glucose metabolism, and lipid metabolism. This suggested potential as an exercise mimetic for patients who are physically unable to exercise. Additional research has shown AICAR activates the AMPK-PGC-1-alpha-SIRT3 axis, which is required for increases in mitochondrial proteins and respiratory complex proteins essential for exercise training adaptations.
What to Know
AICAR's side effect profile in humans is not well characterized due to limited human data. The most notable risk is hypoglycemia (low blood sugar) due to increased glucose uptake by muscles, which could be dangerous, especially in people already taking blood sugar-lowering medications. Potential effects on nucleotide synthesis pathways have also been noted in research.
AICAR has effects beyond AMPK activation that impact purine and pyrimidine synthesis and other metabolic pathways, which may contribute to unexpected side effects. Long-term effects are unknown. The animal research doses (500 mg/kg/day) are impractical and potentially unsafe for humans -- community protocols use much lower doses that are not clinically validated. AICAR is banned by WADA and was added to the prohibited list in 2009.
Do not use if you are a competitive athlete subject to drug testing, have hypoglycemia or blood sugar regulation issues, are taking insulin or diabetes medications (additive blood-sugar-lowering effects could be dangerous), or are pregnant or breastfeeding. Use caution with cardiovascular conditions, liver or kidney impairment, metabolic disorders, or concurrent medications affecting glucose metabolism. Lactic acidosis has been reported with related compounds.
Research References
AMPK and PPARdelta agonists are exercise mimetics
Narkar VA, Downes M, Yu RT, et al. · Cell · 2008
Landmark study showing sedentary mice treated with AICAR for 4 weeks increased running endurance by 44% without training, induced 32 genes linked to oxidative metabolism, and decreased fat mass through the AMPK-PPARdelta pathway.
View StudyAICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review
Visnjic D, Lalic H, Dembitz V, Tomic B, Smoljo T · Cells · 2021
Systematic review confirming AICAR as one of the most commonly used AMPK activators while documenting important AMPK-independent effects on purine and pyrimidine synthesis, emphasizing the need for caution in interpreting AICAR research.
View StudyAdministration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy
Hinder LM, et al. · International Journal of Molecular Sciences · 2024
Showed AICAR prevented and reversed diabetic peripheral neuropathy in Type 1 and Type 2 diabetes mouse models by regulating mitochondrial function through AMPK phosphorylation, with improvements in insulin sensitivity and metabolic parameters.
View StudyAMP-activated protein kinase controls exercise training- and AICAR-induced increases in SIRT3 and MnSOD
Brandauer J, et al. · Frontiers in Physiology · 2015
Demonstrated that AMPK activation by AICAR is required for increases in SIRT3 and MnSOD protein abundance and mitochondrial respiratory complex proteins, establishing a key pathway for exercise training adaptations.
View Study